Alzheimer's and Parkinson's Disease

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Product Segments
• Anti-Alzheimer' s Disease Drugs
• Cholinesterase Inhibitors
• NMDARA
• Anti-Parkinson' s Disease Drugs
• Dopaminergic Agents (Levodopa/Carbidopa)
• Dopamine Agonists
• Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine Amplifiers)
• COMT Inhibitors
• MAO-B Inhibitors
• Dopamine Amplifiers

II. EXECUTIVE SUMMARY

1. Outlook

• Current and Future Analysis

2. Neurodegenerative Diseases Market -

• Key Brands in NDD Market
• Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart)
• Factors Affecting Market
• Major Growth Drivers
• Major Growth Inhibitors
• Market Trends
• High Prevalence Rates Drive Market Growth
• Rapid Growth of Ageing Population
• Price Hikes and Government Caps
• Combination Therapy Gaining Ground
• Research & Development
• Future Holds Promise

3. Alzheimer' s Market Overview

• A Peek at Anti-AD Drug Market
• Impact of Dementia
• Epidemiology
• Table 2: World Alzheimer' s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart)
• Table 3: Alzheimer' s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ' 000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart)
• Table 4: Alzheimer' s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart)
• Patient Growth Drivers
• Demographics Spell Opportunities
• High Growth Rates for AD Drugs
• The Impact of Aricept
• Epic of NMDARA
• Strengths
• Weaknesses
• Future Therapies
• How Successful will the Late Stage Therapies be?
• A Geographic Milieu
• US
• Europe
• Japan
• Alternative Drug Delivery Technologies Gaining Ground
• Transdermal Patch
• Domination of Acetyl Cholinesterase Inhibitors
• Dramatic Changes in Market Lie Ahead
• Advances in Next-Generation Treatments
• Beta Amyloid Hypothesis
• Growth Drivers
• Ageing Baby Boomers Drive AD Market
• Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart)
• New Hypothesis Enables Effective Treatment
• Unmet Medical Needs Drive Market Growth
• Growth Inhibitors
• Link with Other Aliments
• Misdiagnosis
• Patient Awareness
• Medical Refunds
• Competitive Landscape
• Pharmaceutical Majors Rule the Market
• Eisai/Pfizer
• Novartis
• Shire/Johnson & Johnson
• Lundbeck/Forest
• Ipsen and UCB
• Table 6: Leading Brands in the Global Anti- Alzheimer' s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart)
• Year of Approval of AD Drugs in Leading Countries
• Compounds in Pipeline
• Outlook for AD Drugs Market

4. Parkinson' s Disease Market Overview

• An Alluring Market
• Prevalence
• Table 7: World Parkinson' s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart)
• Current Treatments
• New Medicines on the Horizon
• New Findings
• Product Launches Through 2009
• Dominance of Dopamine Agonists
• Revival Revels in Other Anti-PD Drugs Segment
• COMT Inhibitors Growing Fastest
• Key Market Drivers
• Rising Awareness Magnifies Patient Base
• Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth
• The Debut of Stalevo
• Unmet Clinical Needs Show Mammoth Prospects
• Key Market Inhibitors
• Limitations of Existing Medicines Inhibit Market Growth
• Under-Diagnosis Restrains Market Potential
• Generic Competition from L-Dopa and Carbidopa Curbs Market Growth
• Restricted Term of Dopamine Agonists Usage Delays Market Growth

5. Disease Overview

• Alzheimer' s Disease
• Definition
• The Cause
• Finding AD
• Prevention
• Treatment
• Parkinson' s Disease
• Definition
• Pathophysiology
• Diagnosis
• Prevalence
• Treatment
• Surgical Intervention

6. Drug Classification

• Anti-Alzheimer' s' Disease Drugs
• NMDARA
• Memantine
• Cholinesterase Inhibitors (ChEIs)
• Donepezil (Aricept)
• Rivastigmine (Exelon)
• Galantamine Hydrobromide (Razadyne)
• Tacrine (Cognex)
• Other Alternatives
• Vitamin E
• Estrogen Therapy
• Anti-Inflammatory Drugs
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Antioxidants
• Vaccine
• Gingko Biloba
• Pure Medical Nicotine
• Anti-Parkinson' s Disease Drugs
• Dopaminergic agents
• Levodopa/Carbidopa
• Dopamine Agonists
• Pergolide/Permax
• Bromocriptine/Parlodel
• Ropinirole/Requip
• Pramipexole/Mirapex
• Cabergoline/Dostinex
• Apomorphine/Apokyn
• Other Dopamine Agonists
• Other PD Drugs
• COMT Inhibitors
• Tolcapone (Tasmar)
• Entacapone (Comtan)
• MAO-B Inhibitors
• Dopamine Amplifiers
• Anticholinergics

7. Future Therapies

• Alzheimer' s Disease
• Key Pipeline Products
• Phenserine
• Ropern
• Alzhemed
• MEM 1003
• Ampakine Compounds
• Parkinson' s Disease
• Key Pipeline Products
• Adenosine A2a Antagonist
• Spheramine®
• Safinamide
• O-1369

8. New Findings

• Risedronate Minimizes Risk of Hip Fractures in PD Patients
• Researchers Identify New Genes Responsible for AD
• Researchers Establish a New Link Between Loneliness and AD
• Researchers Try to Identify Early Stages of AD
• SORL1 - The New Gene Found to be Responsible for AD
• Scientists Conduct Research Work on CERE-120 Gene Therapy
• Researchers Find New Snail Toxin for Nervous System Disorders
• Researchers Study Anti-PD Properties of Nicotine
• Researchers Establish New Link Between Pesticides and PD
• Study Relates AD to the Quantity of Amyloid Protein
• Researchers Establish Effectiveness of Gene Therapy on AD Patients
• Scientists Use Electric Current to Treat PD Patients
• Scientists Prove Earlier Assumptions Wrong
• Scientists Discover 2 Distinct Types of MCIs

9. Recent Industry Activity

• Eisai Acquires MGI Pharma
• Eli Lilly Begins Phase III Clinical Trial of Alzheimer' s Disease Treatment
• Merz Licenses Anti-Alzheimer' s Drug Technology from TAU
• Eisai Acquires Morphotek
• Transition Therapeutics Acquires NeuroMedix
• Evotec Teams Up with Boehringer Ingelheim
• Siemens Signs Partnership Agreement with Wyeth
• Digilab Receives Notice of Allowance for New Alzheimer' s Biomarker
• Pfizer Joins Forces with Genizon
• Intellect Signs Licensing Agreement with IBL
• Boehringer Ingelheim signs R&D agreement with Ablynx
• Avicena Teams Up with NINDS for Phase III Trial of PD-02
• Prana Begins Phase II clinical trial for PBT2
• Idera Teams Up with Merck
• Merck Signs R&D Agreement with Neuroptix
• Neuro-Hitech Takes Over Q-RNA
• Neurogen Inks Licensing Agreement with Wyeth
• Acumen Revises License Agreement with Merck
• Newron Begins 2nd Phase III clinical trial for Safinamide
• Newron Inks Global Licensing Agreement with Serono
• Pfizer Inks License Agreement with TransTech
• CeNeS Renews R&D Agreement with Tripos
• Athenagen Acquires Zapaq
• Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591
• Teva Receives Health Canada Clearance for Azilect
• Valeant Introduces Zelapar Anti-PD Tablets in the US
• Merck to Halt Further Development of Anti-PD Drug Called Sarizotan
• Amarin Obtains Global Rights for New Apomorphine Formulation
• FDA Clears Exelon for Parkinson' s Disease
• Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112
• Pfizer Takes Over Rinat
• TorreyPines Begins 2nd Phase-I clinical trial for NGX267
• Kyowa Hakko Inks Licensing Agreement with Britannia
• Schwarz Pharma Receives EMEA Clearance for Neupro
• Evotec Inks Licensing Agreement with Roche
• RheoGene Receives Funds from MJFF
• Eisai Initiates Phase I clinical trial for E2012
• Apokyn® Receives Approval in North America
• FDA Approves Azilect
• Voyager Completes Phase II Study for of Leuprolide Acetate
• New Discovery for the Treatment of Alzheimer' s Disease in Canada
• Ortho-McNeil Launches Razadyne™ ER
• Flurizan Enters Phase II Clinical Trials
• Axonyx Releases Supplementary Results of Phase III Trial for Phenserine
• Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist
• BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinson' s Animal Models
• Predix' s PRX-03140 Completes First Clinical Trial in Alzheimer' s Disease
• Galapagos and Senexis Expand Collaboration
• Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch
• Neurologix Posts Interim Results of Phase I Gene Therapy
• GB Therapeutics Receives License for CHF1512
• Alzhemed™ Begins Phase III Trials
• Newron Commences Phase III Trial With Safinamide
• Ceregene Bags FDA Approval for Gene Therapy Alzheimer' s Study
• Memantine Drug Receives Approval from FDA for Treatment of Alzheimer' s
• FDA Grants Fast Track Designation
• Ester Neurosciences Joins Forces with Pharmacopeia

10. Focus on Select Players

• Boehringer Ingelheim (Germany)
• Bristol-Myers Squibb Co. (USA)
• Eisai Inc. (USA)
• Eli Lilly and Company (USA)
• Forest Pharmaceuticals (USA)
• GlaxoSmithKline PLC (UK)
• H. Lundbeck A/S (Denmark)
  • Merz Pharmaceuticals GMBH (Germany)
  • Novartis AG (Switzerland)
  • Ortho-McNeil Neurologics, Inc. (USA)
  • Pfizer Inc (US)
  • Roche (Switzerland)
  • Shire Pharmaceuticals Group PLC (UK)
  • Valeant Pharmaceuticals International (USA)

11. Global Market Perspective

• Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 9: World Long-term Projections for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer' s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Anti-Alzheimer' s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer' s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 14: World Long-term Projections for Anti-Alzheimer' s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 15: World 10-Year Perspective for Anti-Alzheimer' s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Anti-Alzheimer' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012
• Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart)
• Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 22: World 9-Year Perspective for NMDARA (N-methyl, D- Aspartate Receptor Antagonists)) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson' s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 24: World Long-term Projections for Anti-Parkinson' s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson' s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 26: World Long-term Projections for Anti-Parkinson' s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 27: World 10-Year Perspective for Anti-Parkinson' s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 28: World 10-Year Perspective for Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 36: World Long-term Projections for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Current & Future Analysis
  • AD Market Overview
  • Approval of Cholinesterase Inhibitors for MCI to Drive Market
  • Competitive Landscape
  • Table 38: Leading Therapeutics in the North American Alzheimer' s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart)
  • Status of AD Drugs
  • New Products in Clinical Trails
  • Prevalence
  • Table 39: Alzheimer' s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart)
  • PD Therapies Market
  • Levodopa/Carbidopa on Declining Spree
  • Competition
  • Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart)
  • Patent Expiry Status
  • Patent Expiry Status of Parkinson' s Disease Drugs in the US
  • New Brands and Pipeline Analysis
  • PD Prevalence
  • New Findings
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 42: US Long-term Projections for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 43: US 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 45: Canadian Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 46: Canadian 10-Year Perspective for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 48: Japanese Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D- Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 49: Japanese 10-Year Perspective for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • Alzheimer' s Disease
  • Table 50: European Alzheimer' s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ' 000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)
  • Parkinson' s Disease
  • Table 51: European Parkinson' s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ' 000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)
  • Competitive Scenario
  • Table 52: Leading Brands in the European Alzheimer' s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart)
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 54: European Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 56: European Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. Germany

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 60: German Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 61: German 10-Year Perspective for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. France

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
• B. Market Analytics
  • Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti- Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 63: French Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti- Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 64: French 10-Year Perspective for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. United Kingdom

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • New Findings
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti- Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 66: UK Long-term Projections for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti- Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 67: UK 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. Italy

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 69: Italian Long-term Projections for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugsby Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 70: Italian 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti- Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
• B. Market Analytics
  • Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 72: Spanish Long-term Projections for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 73: Spanish 10-Year Perspective for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti- Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Rest of Europe

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • New Findings
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti- Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer' s and Anti- Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 76: Rest of Europe 10-Year Perspective for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Rest of World

• A. Market Analysis
  • Current & Future Analysis
  • Prevalence
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti- Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 78: Rest of World Long-term Projections for Anti- Alzheimer' s & Anti-Parkinson' s Disease Drugs by Product Segment - Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 79: Rest of World 10-Year Perspective for Anti- Alzheimer' s and Anti-Parkinson' s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE